SEC Form 4 · accession 0000899243-17-005252
BIODELIVERY SCIENCES INTERNATIONAL INC · BDSI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Francis E Odonnell Jr.
Director
Period of report
Feb 15, 2017
Accepted (ET)
Feb 24, 2017 · 6:00 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001103021
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 15, 2017 | A | 7,965 | $0.00 | A | 147,636 | D | |
| Common StockF2 | Feb 15, 2017 | M | 70,000 | $0.00 | A | 217,636 | D | |
| Common StockF3 | Feb 15, 2017 | M | 48,419 | $0.00 | A | 266,055 | D | |
| Common StockF4 | Feb 15, 2017 | M | 133,334 | $0.00 | A | 399,389 | D | |
| Common StockF6 | Feb 15, 2017 | S | 39,544 | $1.95 | D | 359,845 | D | |
| Common StockF7 | Feb 16, 2017 | S | 83,900 | $1.89 | D | 275,945 | D | |
| Common Stock | Feb 17, 2017 | S | 6,416 | $1.85 | D | 269,529 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock Units | $0.00 | Feb 15, 2017 | A | 7,965 | D | Feb 15, 2017 | Feb 15, 2017 | Common Stock | 7,965 | 0 | D |
| Restricted Stock Units | $0.00 | Feb 15, 2017 | M | 70,000 | D | Feb 15, 2017 | Feb 15, 2017 | Common Stock | 70,000 | 0 | D |
| Restricted Stock Units | $0.00 | Feb 15, 2017 | M | 48,419 | D | Feb 15, 2017 | Sep 13, 2017 | Common Stock | 48,419 | 48,418 | D |
| Restricted Stock Units | $0.00 | Feb 15, 2017 | M | 133,334 | D | Feb 15, 2017 | Feb 23, 2018 | Common Stock | 133,334 | 266,666 | D |
Explanation of responses
- F1The shares of common stock reported on this Form 4 were acquired by the Reporting Person in connection with the vesting of Restricted Stock Units ("RSUs") granted to the Reporting Person under the Issuer's Long Term Incentive Plan. Pursuant to a deferral, these RSUs vested on February 15, 2017.
- F2The shares of common stock were acquired by the Reporting Person as a result of the vesting of 70,000 RSUs granted to the Reporting Person on February 20, 2013 under the Issuer's 2011 Equity Incentive Plan, as amended (the "Plan"). Pursuant to a deferral, these RSUs vested on February 15, 2017.
- F3The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-half of the RSUs granted to the Reporting Person on February 22, 2014 under the Plan. Pursuant to a deferral, these RSUs vested on February 15, 2017. Pursuant to a deferral, the remaining half of the RSUs under this grant will vest on September 13, 2017.
- F4The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the RSUs granted to the Reporting Person on February 23, 2015 under the Plan. Pursuant to a deferral, these RSUs vested on February 15, 2017. Pursuant to a deferral, the remainder of the RSUs under this grant will vest in equal portions on each of (i) September 14, 2017 and (ii) February 23, 2018.
- F5The shares of common stock were sold under a pre-planned 10b5-1 trading plan and were sold to cover the Reporting Person's tax liability upon the vesting of RSUs.
- F6On February 15, 2017, the Reporting Person sold an aggregate of 39,544 shares of the Issuer's Common Stock at a weighted average price of $1.95 per share. The highest sale price for the Common Stock was $2.00 per share and the lowest sale price was $1.90 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F7On February 16, 2017, the Reporting Person sold an aggregate of 83,900 shares of the Issuer's Common Stock at a weighted average price of $1.89 per share. The highest sale price for the Common Stock was $1.95 per share and the lowest sale price was $1.85 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.